Could a diabetes drug boost heart ablation success?

NCT ID NCT07389941

Not yet recruiting Disease control Sponsor: University of Luebeck Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking semaglutide (a drug used for diabetes and weight loss) before a standard heart procedure called catheter ablation can help prevent atrial fibrillation from coming back. The trial will include 240 adults with obesity and symptomatic atrial fibrillation who are having their first ablation. Participants will receive either semaglutide plus ablation or standard care alone, and researchers will check heart rhythm after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (a drug for weight and diabetes management)
What this could lead to: If it works, this could show that pre-treatment with semaglutide helps prevent atrial fibrillation from returning after ablation in people with obesity.
What could go wrong: This is a Phase 4 trial, but it's not yet recruiting and has a moderate size (240 participants). The benefit may be small or not apply to all patients, and semaglutide can cause side effects like nausea or gastrointestinal issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF)

More trials for these conditions

Other studies related to the condition(s) this trial covers.